Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""receptor, ErbB-2"" wg kryterium: Temat


Tytuł:
[Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
Autorzy:
Wei T; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yuan P; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Mar 23; Vol. 46 (3), pp. 211-220.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*
Urinary Bladder Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Immunoconjugates*/therapeutic use
Receptor, ErbB-2*
Humans ; Oncogenes
Czasopismo naukowe
Tytuł:
Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors.
Autorzy:
Feldman D; Faculty of Medicine, The Technion Institute of Technology, Haifa, Israel.
Sinberger LA; Department of Molecular Biology, Ariel University, Ariel, Israel.
Salmon-Divon M; Department of Molecular Biology, Ariel University, Ariel, Israel.; Adelson School of Medicine, Ariel University, Ariel, Israel.
Ben-Dror J; Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Shachar SS; Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.; School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sonnenblick A; Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. .; School of Medicine, Tel Aviv University, Tel Aviv, Israel. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Oct 24; Vol. 23 (1), pp. 1031. Date of Electronic Publication: 2023 Oct 24.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/metabolism
Breast Neoplasms*/pathology
Humans ; Female ; RNA ; Retrospective Studies ; Immunohistochemistry ; Polymerase Chain Reaction
Czasopismo naukowe
Tytuł:
Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain.
Autorzy:
Cruz VL; BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
Souza-Egipsy V; BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
Gion M; University Hospital Ramon y Cajal, 28304 Madrid, Spain.
Pérez-García J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, 08017 Barcelona, Spain.; Medical Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain.
Cortes J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, 08017 Barcelona, Spain.; Medical Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain.; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, 28108 Madrid, Spain.
Ramos J; BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
Vega JF; BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/Serrano 113 bis, 28006 Madrid, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 27; Vol. 24 (15). Date of Electronic Publication: 2023 Jul 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*
Receptor, ErbB-2*/metabolism
Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols ; Trastuzumab
Czasopismo naukowe
Tytuł:
HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.
Autorzy:
Pous A; Department of Medical Oncology, Institut Català d'Oncologia (ICO) Badalona, 08916 Badalona, Spain.; Badalona Applied Research Group in Oncology (B-ARGO), 08916 Badalona, Spain.
Notario L; Department of Medical Oncology, Institut Català d'Oncologia (ICO) Badalona, 08916 Badalona, Spain.; Badalona Applied Research Group in Oncology (B-ARGO), 08916 Badalona, Spain.
Hierro C; Department of Medical Oncology, Institut Català d'Oncologia (ICO) Badalona, 08916 Badalona, Spain.; Badalona Applied Research Group in Oncology (B-ARGO), 08916 Badalona, Spain.
Layos L; Department of Medical Oncology, Institut Català d'Oncologia (ICO) Badalona, 08916 Badalona, Spain.; Badalona Applied Research Group in Oncology (B-ARGO), 08916 Badalona, Spain.
Bugés C; Department of Medical Oncology, Institut Català d'Oncologia (ICO) Badalona, 08916 Badalona, Spain.; Badalona Applied Research Group in Oncology (B-ARGO), 08916 Badalona, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 13; Vol. 24 (14). Date of Electronic Publication: 2023 Jul 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Immunoconjugates*/therapeutic use
Receptor, ErbB-2*/antagonists & inhibitors
Stomach Neoplasms*/drug therapy
Humans ; Immunotherapy ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use
Czasopismo naukowe
Tytuł:
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.
Autorzy:
Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Corso S; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Franceschini A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Raimondi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy.
Bellomo SE; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Dugo M; Department of Medical Oncology-Breast Cancer Unit Clinical Translational and Immunotherapy Research, IRCCS Ospedale San Raffaele, Milan, Italy.
Morano F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy.
Prisciandaro M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy.
Brich S; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Belfiore A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Vingiani A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Di Bartolomeo M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy.
Pruneri G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Giordano S; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy. .
Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. .
Pokaż więcej
Źródło:
Cellular oncology (Dordrecht) [Cell Oncol (Dordr)] 2023 Jun; Vol. 46 (3), pp. 661-676. Date of Electronic Publication: 2023 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/metabolism
Stomach Neoplasms*/pathology
Animals ; Mice ; Trastuzumab/pharmacology ; Fatty Acid Synthases/metabolism ; Fatty Acid Synthases/therapeutic use ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
The Prognostic Effect of HER2 Gene Amplification in High-Grade Endometrial Carcinomas and its Correlation with Protein Overexpression.
Autorzy:
Bozkurt KK; Department of Pathology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
Çiriş İM; Department of Pathology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
Başpınar Ş; Department of Pathology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
Çetin B; Department of Medical Oncology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
Erdemoğlu E; Department of Gynecologic Oncology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
Bircan S; Department of Pathology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
Ertunç O; Department of Pathology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
Pokaż więcej
Źródło:
International journal of surgical pathology [Int J Surg Pathol] 2023 Jun; Vol. 31 (4), pp. 365-374. Date of Electronic Publication: 2022 May 25.
Typ publikacji:
Journal Article
MeSH Terms:
Biomarkers, Tumor*/genetics
Endometrial Neoplasms*/diagnosis
Endometrial Neoplasms*/genetics
Endometrial Neoplasms*/metabolism
Receptor, ErbB-2*/metabolism
Female ; Humans ; Gene Amplification ; In Situ Hybridization, Fluorescence ; Prognosis
Czasopismo naukowe
Tytuł:
Real-world clinical outcomes of the combination of anti-PD-1 antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer.
Autorzy:
Yang J; The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Shi Z; The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Zhang X; The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Liu Q; The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Cui X; The Department of Pathology of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Li L; The Department of Pathology of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Liu B; The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Wei J; The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (8), pp. 9517-9526. Date of Electronic Publication: 2023 Mar 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Receptor, ErbB-2*/metabolism
Stomach Neoplasms*/pathology
Humans ; Trastuzumab/adverse effects ; Retrospective Studies ; Esophagogastric Junction/pathology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer.
Autorzy:
Peg V; Pathology Department, Vall d'Hebron University Hospital, Passeo Vall d'Hebron, 119-129, 08035, Barcelona, Spain. .; Autonomous University of Barcelona, Barcelona, Spain. .; Spanish Biomedical Research Centre in Cancer (CIBERONC), Madrid, Spain. .
Moline T; Pathology Department, Vall d'Hebron University Hospital, Passeo Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Roig M; Pathology Department, Vall d'Hebron University Hospital, Passeo Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Saruta Y; Sysmex R&D Center Europe GmbH, Hamburg, Germany.
Cajal SRY; Pathology Department, Vall d'Hebron University Hospital, Passeo Vall d'Hebron, 119-129, 08035, Barcelona, Spain.; Autonomous University of Barcelona, Barcelona, Spain.; Spanish Biomedical Research Centre in Cancer (CIBERONC), Madrid, Spain.
Pokaż więcej
Źródło:
Diagnostic pathology [Diagn Pathol] 2024 Feb 15; Vol. 19 (1), pp. 32. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/diagnosis
Humans ; Female ; In Situ Hybridization, Fluorescence/methods ; Retrospective Studies ; Neoplasm Recurrence, Local/genetics ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Monosomy ; Gene Amplification
Czasopismo naukowe
Tytuł:
Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression.
Autorzy:
Tozbikian G; From the Department of Pathology, The Ohio State University, Wexner Medical Center, Columbus (Tozbikian).
Krishnamurthy S; the Department of Pathology (Krishnamurthy), The University of Texas MD Anderson Cancer Center, Houston.
Bui MM; the Department of Pathology, Moffitt Cancer Center & Research Institute, Tampa, Florida (Bui).
Feldman M; the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Feldman).
Hicks DG; the Department of Pathology, University of Rochester Medical Center, Rochester, New York (Hicks).
Jaffer S; the Department of Pathology, Mount Sinai Medical Center, New York, New York (Jaffer).
Khoury T; the Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York (Khoury).
Wei S; the Department of Pathology, University of Kansas Medical Center; Kansas City (Wei).
Wen H; the Department of Pathology, Memorial Sloan Kettering Cancer Center; New York, New York (Wen).
Pohlmann P; the Department of Breast Medical Oncology (Pohlmann), The University of Texas MD Anderson Cancer Center, Houston.
Pokaż więcej
Źródło:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2024 Feb 01; Vol. 148 (2), pp. 242-255.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Humans ; Female ; In Situ Hybridization, Fluorescence ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Gene Amplification ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism
Czasopismo naukowe
Tytuł:
Genomic Alterations of Tumors in HER2-Low Breast Cancers.
Autorzy:
Tsai YF; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan.
Huang CC; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; School of Public Health, College of Public Health, National Taiwan University, Taipei 112201, Taiwan.
Hsu CY; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan.; Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; College of Nursing, National Taipei University of Nursing and Health Sciences, Taipei 112201, Taiwan.
Feng CJ; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan.; Division of Plastic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
Lin YS; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
Chao TC; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan.; Division of Chemotherapy, Department of Oncology, Taipei 112201, Taiwan.
Lai JI; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan.; Division of Chemotherapy, Department of Oncology, Taipei 112201, Taiwan.
Lien PJ; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
Liu CY; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan.; Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
Chiu JH; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Division of General Surgery, Department of Surgery, Cheng-Hsin General Hospital, Taipei 112201, Taiwan.
Tseng LM; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan.; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 21; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 21.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/metabolism
Female ; Humans ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Genomics ; Mutation ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Receptors, Progesterone/metabolism
Czasopismo naukowe
Tytuł:
USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Autorzy:
Kuang X; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Salinger A; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Benavides F; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Muller WJ; Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Canada.; Department of Biochemistry, McGill University, Montreal, Canada.; Faculty of Medicine, McGill University, Montreal, Canada.
Dent SYR; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.; The University of Texas MD Anderson Cancer Center/UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, United States of America.
Koutelou E; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.; Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Jan 18; Vol. 19 (1), pp. e0290837. Date of Electronic Publication: 2024 Jan 18 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Mammary Neoplasms, Experimental*/pathology
Mice ; Rats ; Female ; Humans ; Animals ; Mice, Transgenic ; Mammary Tumor Virus, Mouse/genetics ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Cell Transformation, Neoplastic/genetics ; Carcinogenesis/genetics ; Ubiquitin Thiolesterase/genetics
Czasopismo naukowe
Tytuł:
Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Autorzy:
Xiong M; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Wang X; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Liu D; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiu B; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhang Q; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Chi W; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Goh CW; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhang L; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Chen M; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Ren H; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Shao ZM; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Yang B; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Wu J; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.; Collaborative Innovation Center for Cancer Medicine, Shanghai, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Jan; Vol. 13 (2), pp. e6955.
Typ publikacji:
Journal Article
MeSH Terms:
Neoadjuvant Therapy*
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Humans ; Female ; Retrospective Studies ; China ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Prognosis ; Mutation ; Tumor Suppressor Protein p53/genetics
Czasopismo naukowe
Tytuł:
HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.
Autorzy:
Sanguedolce F; Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Zanelli M; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Palicelli A; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Bisagni A; Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Zizzo M; Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Ascani S; Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.
Pedicillo MC; Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Cormio A; Urology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, 60126 Ancona, Italy.
Falagario UG; Department of Urology and Renal Transplantation, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Carrieri G; Department of Urology and Renal Transplantation, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Cormio L; Department of Urology and Renal Transplantation, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.; Department of Urology, Bonomo Teaching Hospital, 76123 Andria, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Feb 13; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Humans ; Biomarkers, Tumor/metabolism ; Prognosis ; Urinary Bladder/pathology
Czasopismo naukowe
Tytuł:
HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review.
Autorzy:
Gonullu B; Université Paris Cité, INSERM, UMR_S942 MASCOT, 75006 Paris, France.; Faculty of Medicine, Yeditepe University, Istanbul 34755, Turkey.
Angeli E; Université Paris Cité, INSERM, UMR_S942 MASCOT, 75006 Paris, France.; Université Sorbonne Paris Nord, 9 Avenue Jean Baptiste Clément, 93439 Villetaneuse, France.; Service d'Oncologie Médicale, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, 93000 Bobigny, France.
Pamoukdjian F; Université Paris Cité, INSERM, UMR_S942 MASCOT, 75006 Paris, France.; Université Sorbonne Paris Nord, 9 Avenue Jean Baptiste Clément, 93439 Villetaneuse, France.; Service de Médecine Gériatrique, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, 93000 Bobigny, France.
Bousquet G; Université Paris Cité, INSERM, UMR_S942 MASCOT, 75006 Paris, France.; Université Sorbonne Paris Nord, 9 Avenue Jean Baptiste Clément, 93439 Villetaneuse, France.; Service d'Oncologie Médicale, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, 93000 Bobigny, France.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Feb 10; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 10.
Typ publikacji:
Meta-Analysis; Journal Article; Review; Systematic Review
MeSH Terms:
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Neoadjuvant Therapy*/methods
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Radiogenomic analysis of prediction HER2 status in breast cancer by linking ultrasound radiomic feature module with biological functions.
Autorzy:
Cui H; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Sun Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Zhao D; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Zhang X; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Kong H; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Hu N; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Wang P; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Zuo X; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Fan W; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Yao Y; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Fu B; Department of Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Tian J; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Wu M; Department of Clinical Medicine, The Second Affiliated Hospital of Harbin Medical University, Heilongjiang, 150086, China.
Gao Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Ning S; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Zhang L; Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Jan 24; Vol. 21 (1), pp. 44. Date of Electronic Publication: 2023 Jan 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*/diagnostic imaging
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Imaging Genomics*
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Female ; Humans ; Magnetic Resonance Imaging ; Retrospective Studies ; Ultrasonography, Mammary
Czasopismo naukowe
Tytuł:
Inhibition of mutationally activated HER2.
Autorzy:
Collins SJ; Department of Physiology and Biophysics, Stony Brook University, Stony Brook, New York, USA.
Guo J; Department of Applied Mathematics & Statistics, Stony Brook University, Stony Brook, New York, USA.
Rizzo RC; Department of Applied Mathematics & Statistics, Stony Brook University, Stony Brook, New York, USA.; Laufer Center for Physical & Quantitative Biology, Stony Brook University, Stony Brook, New York, USA.; Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, New York, USA.
Miller WT; Department of Physiology and Biophysics, Stony Brook University, Stony Brook, New York, USA.; Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, New York, USA.; Department of Veterans Affairs Medical Center, Northport, New York, USA.
Pokaż więcej
Źródło:
Chemical biology & drug design [Chem Biol Drug Des] 2023 Jan; Vol. 101 (1), pp. 87-102. Date of Electronic Publication: 2022 Aug 27.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Neoplasms*
Humans ; Protein Binding ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy.
Autorzy:
Pang J; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Ding N; Department of Clinical Laboratory, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Yin N; Department of Operating Room, First People's Hospital of Changde, Changde, China.
Xiao Z; Department of Breast Surgery, Xiangya Hospital, Central South University, 87# Xiangya Road, Changsha, 410008, Hunan, China. .; Clinical Research Center for Breast Cancer in Hunan Province, Changsha, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 19; Vol. 14 (1), pp. 6578. Date of Electronic Publication: 2024 Mar 19.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Humans ; Female ; Trastuzumab/therapeutic use ; Prognosis ; Receptor, ErbB-2 ; Inflammation/drug therapy ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Autorzy:
Nguyen AQ; Department of Health Policy and Economics, Hanoi University of Public Health, Hanoi, Vietnam.
Tran OTM; Vietnam Strategy and Planning Institute, Hanoi, Vietnam.
Nguyen PK; Vietnam Strategy and Planning Institute, Hanoi, Vietnam.
Nguyen HT; Department of Health Policy and Economics, Hanoi University of Public Health, Hanoi, Vietnam.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 15; Vol. 19 (3), pp. e0300474. Date of Electronic Publication: 2024 Mar 15 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Biosimilar Pharmaceuticals*/therapeutic use
Humans ; Female ; Trastuzumab/therapeutic use ; Cost-Benefit Analysis ; Vietnam ; Receptor, ErbB-2 ; Antibodies, Monoclonal, Humanized/therapeutic use ; Chemotherapy, Adjuvant ; Quality-Adjusted Life Years
Czasopismo naukowe
Tytuł:
Prognostic value and relapse pattern of HER2-low in hormone receptor-positive breast cancer.
Autorzy:
Wei T; Department of VIP Medical, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kang Y; Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Wang X; Department of VIP Medical, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yue J; Department of VIP Medical, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xu B; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuan P; Department of VIP Medical, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (7), pp. 550-558. Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Humans ; Female ; Prognosis ; Receptor, ErbB-2 ; Disease-Free Survival ; Recurrence
Czasopismo naukowe
Tytuł:
Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer.
Autorzy:
Tseng YF; From the Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan (Tseng, Lee, Hu, Zhang, Hung, Lien).
Li YC; the Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan (Li, Lien).
Lee YH; From the Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan (Tseng, Lee, Hu, Zhang, Hung, Lien).
Hu HW; From the Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan (Tseng, Lee, Hu, Zhang, Hung, Lien).
Zhang MS; From the Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan (Tseng, Lee, Hu, Zhang, Hung, Lien).
Hung TC; From the Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan (Tseng, Lee, Hu, Zhang, Hung, Lien).
Lien HC; the Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan (Li, Lien).
Pokaż więcej
Źródło:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2024 Mar 01; Vol. 148 (3), pp. e48-e56.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Humans ; Female ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Immunohistochemistry ; In Situ Hybridization, Fluorescence/methods ; Receptor, ErbB-2/metabolism ; RNA
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies